The patent entitled, ‘Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker" is still pending.
Ventrus chairman and CEO Russell Ellison said this is a significant milestone for their company, since this provides patent protection in the US for the method of treatment, recited in the allowed claims, for the topical application of VEN 307 (2% diltiazem cream) for the treatment of anal fissures.